title: Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
abstract: We report a case of therapeutic drug monitoring guided raltegravir use for the prevention of vertical HIV transmission in a premature neonate born to a woman living with perinatally acquired HIV and documented resistance to multiple HIV drugs. Maternal viral load was above 1,000 copies/ml at delivery. This case demonstrates delayed raltegravir elimination in a neonate born at 33 weeks gestational age and a need for less frequent raltegravir dosing than is used in older infants and children.
authors.affiliation: McGill University Health Centre, Chronic Viral Illness Service, Montréal, QC, Canada.|Toronto General Hospital, University Health Network, Immunodeficiency Clinic, Toronto, ON, Canada.|University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada.
authors.forename: Denise
authors.initials: D
authors.lastname: Kreutzwiser
authors.affiliation: McGill University Health Centre, Chronic Viral Illness Service, Montréal, QC, Canada.|McGill University Health Centre, Québec Antiretroviral Therapeutic Drug Monitoring Program, Montréal, QC, Canada.|Université de Montréal, Faculté de Pharmacie, Montréal, QC, Canada.
authors.forename: Nancy
authors.initials: N
authors.lastname: Sheehan
authors.affiliation: Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
authors.forename: Natalie
authors.initials: N
authors.lastname: Dayneka
authors.affiliation: McGill University Health Centre, Chronic Viral Illness Service, Montréal, QC, Canada.|McGill University Health Centre, Québec Antiretroviral Therapeutic Drug Monitoring Program, Montréal, QC, Canada.
authors.forename: Benoît
authors.initials: B
authors.lastname: Lemire
authors.affiliation: McGill University Health Centre, Chronic Viral Illness Service, Montréal, QC, Canada.|McGill University Health Centre, Québec Antiretroviral Therapeutic Drug Monitoring Program, Montréal, QC, Canada.
authors.forename: Alison
authors.initials: A
authors.lastname: Wong
authors.affiliation: Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.|Department of Pediatrics, University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.
authors.forename: Lindy
authors.initials: L
authors.lastname: Samson
authors.affiliation: Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.|Department of Pediatrics, University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.
authors.forename: Jason
authors.initials: J
authors.lastname: Brophy
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D023241:Antiretroviral Therapy, Highly Active; D016903:Drug Monitoring; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000517:prevention & control* / Q000635:transmission* / Q000821:virology; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D056990:Post-Exposure Prophylaxis; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D000068898:Raltegravir Potassium / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D000068898:Raltegravir Potassium